CELLUMED CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,740 KRW | +3.69% |
|
+4.44% | -19.07% |
| Mar. 21 | Cellumed Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 07 | Cellumed Co.,Ltd. announced that it has received KRW 10.000000362 billion in funding | CI |
| Sales 2022 | 122B 88.76M | Sales 2023 | 95.55B 69.47M | Capitalization | 92.01B 66.89M |
|---|---|---|---|---|---|
| Net income 2022 | -5.57B -4.05M | Net income 2023 | -37.3B -27.12M | EV / Sales 2022 | 1.49 x |
| Net Debt 2022 | 184M 134K | Net Debt 2023 | 8.84B 6.43M | EV / Sales 2023 | 1.06 x |
| P/E ratio 2022 |
-31.5
x | P/E ratio 2023 |
-2.45
x | Employees | 103 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.87% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.69% | ||
| 1 week | +4.44% | ||
| Current month | -2.79% | ||
| 1 month | -6.50% | ||
| 3 months | -17.54% | ||
| 6 months | -32.82% | ||
| Current year | -19.07% |
1 week
1 608.00
1 888.00
1 month
1 597.001 922.00
Current year
1 597.002 870.00
1 year
1 597.007 090.00
3 years
1 597.0013 750.00
5 years
1 597.0013 750.00
10 years
1 597.0039 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
In-Soo Yoo
CEO | Chief Executive Officer | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
In-Soo Yoo
CEO | Chief Executive Officer | 62 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1,740 | +3.69% | 869,551 |
| 24-04-24 | 1,678 | +1.51% | 48,718 |
| 24-04-23 | 1,653 | +2.35% | 69,057 |
| 24-04-22 | 1,615 | -0.62% | 76,077 |
| 24-04-19 | 1,625 | -2.46% | 97,305 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
CELLUMED CO., LTD., formerly Korea Bone Bank CO., LTD, is a Korea-based company engaged in the manufacture and sale of medical equipment and biosimilars. The Companyâs products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The Company sells its products within domestic market and to overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.07% | 58.72M | |
| +12.59% | 128B | |
| -10.58% | 10.66B | |
| -0.39% | 8.55B | |
| +13.56% | 7.1B | |
| +25.94% | 5.06B | |
| +6.93% | 3.4B | |
| -1.64% | 3.08B | |
| -11.96% | 2.11B | |
| -7.25% | 2.03B |
- Stock Market
- Equities
- A049180 Stock
